We Develop Complex Formulations Utilizing Our Know-How and Proprietary Technologies

Our products have effectively met the medical needs of patients worldwide, with Lidoderm (a non-opioid 5% Lidocaine Patch) playing a significant role in alleviating the suffering of individuals living with pain associated with Post Herpetic Neuralgia, but our teams are continuing to develop innovative products to address unmet needs in the market. As a California-based pharmaceutical company, we are known for developing and manufacturing complex formulations entirely in-house that are difficult to replicate.

ABOUT TEIKOKU PHARMA

Teikoku Pharma USA (TPU), a subsidiary of Teikoku Seiyaku, Japan, is a family-owned, privately-held international specialty pharmaceutical company founded in 1997 in California.

We develop innovative products in several therapeutic areas, including pain management, CNS disorders, and dermatology, using our proprietary and innovative drug delivery technologies. Our team, includes experts in R&D, clinical, regulatory, and manufacturing.

OUR HISTORY

Teikoku Seiyaku has a storied history of technological innovation and business success.

1848

1918

1938

1957

1974

1988

1993

1995

1997

1999

2000

2003

2007

2014

2017

2022

1848

Shozo Akazawa, the 5th head of the family, is certified by the government to deal in medicines, and starts the business.

1918

Teikoku Seiyaku is established with 1 million yen in capital in Kagawa Prefecture, Japan.

1938

Horxis launches in Japan, a prototype of the current medicated plaster.

1957

Osaka Plant spins off of Teikoku Seiyaku, and with it, Fuso Chemical Industry Co. Ltd.

1974

Teikoku Seiyaku’s medicated plasters are approved for prescription use in Japan, becoming the company’s main product line.

1988

Catlep, Japan’s first transdermal indomethacin plaster for prescription use, is approved and production begins.

1988

New plant (now Plant No. 2), 5 stories and 6,451 square meters, completed at the site of headquarters complex.

1993

Seltouch®, a transdermal felbinac plaster for prescription use, is approved in Japan and production begins.

1995

Non-prescription drug division (OTC) spins off as an independent company, Teikoku Pharmacare, Co. Ltd.

1997

Teikoku Pharma USA is established as a California pharmaceutical company.

1999

FDA grants approval for Lidoderm in the US.

2000

Completion of Plant No. 8 to manufacture topical poultice and matrix plasters.

2003

Fuso Teiyaku is established in Qingdao, China.

2007

Versatis receives MHRA approval in UK, and Flector receives FDA approval in the US.

2014

Completion of Plant No. 9 to manufacture matrix plasters.

2017

Approval of Rupafin® in Japan

2017

Completion of Plant No. 10 to manufacture ointment and cream.

2022

Approval of ALLYDONE® in Japan

Parent Company

Teikoku Seiyaku is a world leader in the research, development, manufacture, and commercialization of pharmaceutical drugs.

Learn More

Management Team

Our company is guided by deep experience and expertise.

Learn More

Scientific Advisory Board

Our work is guided by expert scientists and researchers in their fields.

Learn More

Partnerships

See what opportunities are possible when you partner with Teikoku Pharma.

Learn More

Affiliates

Learn about Teikoku Group and our mission to deliver innovative and safe drug delivery solutions.

Learn More

Careers

Help us improve the lives of patients by joining our growing team.

Learn More

FEATURED NEWS

NEWS

Teikoku Pharma USA, Inc. Announces NMPA Approved Lidoderm® in China on May 8, 2024

Read

NEWS

Teikoku Pharma USA announces positive topline results from Phase 2 clinical trial of TPU-006, non-opioid pain management patch in Abdominoplasty Surgery.

Read

NEWS

President and CEO Misako Fujioka Interviewed in Newsweek International

Read

NEWS

Teikoku Pharma granted FDA Fast Track Designation for TPU-006, a Novel 4-day Dexmedetomidine Transdermal System for Post Operative Pain Management

Read

NEWS

Change in The Board of Directors

Read

NEWS

Notice of Launch of ALLYDONE® Patches 27.5 mg / ALLYDONE® Patches 55 mg in Japan as Japan’s First Donepezil Transdermal Therapeutic System

Read

NEWS

Manufacturing and Marketing Approval Received in Japan for ALLYDONE® Patches for Treatment of Dementia Due to Alzheimer’s Disease as Japan’s First Donepezil Transdermal Therapeutic System

Read

NEWS

Execution of a license agreement on an exclusive marketing right in Japan of the first donepezil transdermal therapeutic system in Japan

Read

NEWS

TEIKOKU SEIYAKU was selected as A Global Niche Top Company by METI in FY2020.

Read

NEWS

Change in The Board of Directors

Read

VIEW ALL

CONTACT US

Contact us for distribution or licensing opportunities, or to learn more about our growing portfolio of life-changing drug therapies.

"*" indicates required fields